Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
06:30am, Monday, 11'th Oct 2021
ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced a definitive agr
Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA
06:45pm, Thursday, 02'nd Sep 2021
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Supernus to Participate in Upcoming September Investor Conferences
09:00am, Thursday, 02'nd Sep 2021
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2021 Results - Earnings Call Transcript
09:12pm, Wednesday, 04'th Aug 2021
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2021 Results - Earnings Call Transcript
Supernus Pharmaceuticals (SUPN) Beats Q2 Earnings and Revenue Estimates
07:50pm, Wednesday, 04'th Aug 2021
Supernus (SUPN) delivered earnings and revenue surprises of 152.94% and 4.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Supernus Announces Second Quarter 2021 Financial Results
04:09pm, Wednesday, 04'th Aug 2021
ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus to Host Second Quarter 2021 Financial Results Conference Call
04:37pm, Thursday, 22'nd Jul 2021
ROCKVILLE, Md., July 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
10:27am, Wednesday, 02'nd Jun 2021
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
Supernus to Present at Jefferies Virtual Healthcare Conference
08:30am, Tuesday, 25'th May 2021
ROCKVILLE, Md., May 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Supernus Pharmaceuticals: Virtuous Cycle Of Free Cash Flow Generation To Fund Product Development And Acquisition
04:35pm, Thursday, 13'th May 2021
We did a comparison of 3 small-cap biotech stocks (SUPN, ENTA & EGRX) which were ranked highly in our quantitative model. SUPN demonstrated outperformance in growth and profitability metrics.
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2021 Results - Earnings Call Transcript
10:57pm, Wednesday, 05'th May 2021
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2021 Results - Earnings Call Transcript
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Miss Estimates
07:56pm, Wednesday, 05'th May 2021
Supernus (SUPN) delivered earnings and revenue surprises of -57.69% and -0.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Supernus Announces Paragraph IV ANDA Filing for XADAGO®
08:49pm, Tuesday, 04'th May 2021
ROCKVILLE, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Supernus to Host First Quarter 2021 Financial Results Conference Call
05:44pm, Tuesday, 27'th Apr 2021
ROCKVILLE, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Supernus (SUPN) Receives FDA Approval for ADHD Treatment
02:24pm, Monday, 05'th Apr 2021
Supernus (SUPN) gets FDA approval for ADHD treatment, Qelbree, in pediatric patients 6 to 17 years of age.
